Relmada Therapeutics (RLMD) Net Income towards Common Stockholders (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Net Income towards Common Stockholders data on file, last reported at -$56.4 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 216.54% year-over-year to -$56.4 million in Q1 2026; TTM through Mar 2026 was -$96.4 million, a 24.78% decrease from a year earlier, with the FY2025 full-year figure at -$64.6 million, up 19.72% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$56.4 million, down from -$20.0 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RLMD reached as high as -$9.9 million in Q2 2025 and fell as low as -$56.4 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$27.7 million across 5 years, with a median of -$24.7 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders surged 69.99% in 2022 and sank 216.54% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$39.1 million in 2022, then jumped by 34.58% to -$25.6 million in 2023, then increased by 27.91% to -$18.4 million in 2024, then slipped by 8.25% to -$20.0 million in 2025, then slumped by 182.54% to -$56.4 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$56.4 million in Q1 2026, -$20.0 million in Q4 2025, and -$10.1 million in Q3 2025.